Vertex Pharmaceuticals (NASDAQ: VRTX) — Company Overview, News & Financial Data
Vertex Pharmaceuticals develops innovative therapies for cystic fibrosis and severe diseases, focusing on improving patient quality of life.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company engaged in discovering, developing, and commercializing transformative medicines for people with serious diseases. The company focuses on scientific innovation to treat life-threatening conditions, with a primary commercial focus on transformative therapies for cystic fibrosis. Beyond cystic fibrosis, the business advances a broad clinical research pipeline spanning gene-editing therapies for sickle cell disease and transfusion-dependent beta thalassemia, non-opioid pain treatments, APOL1-mediated kidney disease therapies, and cell therapies for type 1 diabetes. Operating research laboratories and commercial offices globally, the organization partners with research institutions to expand healthcare solutions.
Snapshot
Operations
Products and/or services of Vertex Pharmaceuticals
- Cystic Fibrosis Treatments: Development and commercial supply of oral small-molecule CFTR modulator therapies including triple and dual combination regimens designed to treat the underlying cause of cystic fibrosis across global markets for pediatric and adult patient populations.
- Gene-Edited Cell Therapies: Ex vivo CRISPR-Cas9 gene-edited cellular treatments authorized for patients with severe sickle cell disease and transfusion-dependent beta thalassemia, administered through specialized qualified treatment centers in North America and Europe.
- Non-Opioid Pain Therapies: Selective small-molecule NaV1.8 voltage-gated sodium channel inhibitors for the management of moderate-to-severe acute pain, offering alternative non-opioid pain treatment options in acute care, surgical, and outpatient medical settings.
- Kidney Disease Pipeline: Clinical-stage small molecule drug candidates targeted at treating APOL1-mediated kidney disease and IgA nephropathy, aiming to reduce proteinuria and slow progressive renal function loss in patients worldwide.
- Type 1 Diabetes Therapies: Allogeneic and autologous stem cell-derived fully differentiated insulin-producing islet cell therapies, evaluated in clinical trials to restore endogenous insulin production and glycemic control without requiring chronic immune suppression.
- Endocrine and Metabolic Programs: Development of targeted small molecule therapies for rare endocrine and metabolic diseases, expanding clinical development into specialized endocrinology and therapeutic areas through internal research and strategic acquisitions.
Vertex Pharmaceuticals executive team
- Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman
- Dr. Reshma Kewalramani FASN, M.D.CEO, President & Director
- Mr. Charles F. Wagner Jr.Executive VP, COO & CFO
- Dr. David M. Altshuler M.D., Ph.D.Executive VP & Chief Scientific Officer
- Dr. Ourania Tatsis Ph.D.Executive VP and Chief Regulatory & Quality Officer
- Ms. Kristen C. Ambrose CPASenior VP & Chief Accounting Officer
- Ms. Susie Lisa C.F.A.Senior Vice President of Investor Relations
- Mr. Jonathan Biller J.D.Executive VP & Chief Legal Officer
- Ms. Nina DevlinSenior VP & Chief Communications Officer
- Ms. Stephanie FranklinSenior VP & Chief Human Resources Officer